Antibody Drug Conjugate market, Industry Analysis, and Forecast to 2035
The potential of antibody drug conjugates for the treatment of various disease indications, including cancer, is being slowly recognized in the pharmaceutical sector. Specifically, the success of these products can be attributed to their ability to effectively identify and eliminate diseased cells, along with low risk of side effects.
The financial opportunity within the antibody drug conjugate market has been analyzed across the following segments:
Target Disease Indication
Acute Lymphoblastic Leukemia
Breast Cancer
B-Cell Lymphoma
Cervical Cancer
Gastric Cancer
Lung Cancer
Multiple Myeloma
Renal Cancer
Other Target Disease Indications
Therapeutic Area
Hematological Cancer
Solid Tumor
Linker
Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)
Maleimide
Maleimidocaproyl
Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate
Tetrapeptide-Based Linker
Valine-Alanine
Valine-Citrulline
Other Linkers
Payload
DM1
DM4
Duocarmycin
Monomethyl auristatin E (MMAE)
Monomethyl auristatin F (MMAF)
Ozogamicin
SG3199
SN-38 / Irinotecan
Other Payloads
Target Antigen
BCMA (TNFRSF17 / BCM)
CD19
CD22
CD30
CD79b
CEACAM5
HER-2 (ERBB2)
Nectin 4
Tissue factor
TROP-2
Other Target Antigen
Key Geographical Regions
North America
Europe
Asia-Pacific and Rest of the World
The Antibody Drug Conjugate Market (7th Edition), 2023-2035 report features the following companies, which we identified to be key players in this domain:
ADC Therapeutics
Astellas Pharma
AstraZeneca
Byondis
Daiichi Sankyo
Genentech
Gilead Sciences
ImmunoGen
Pfizer
RemeGen
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Target Competitiveness Analysis
6. Company and Drug Profiles
7. Clinical Trial Analysis
8. Key Opinion Leaders
9. Combination Therapies
10. Partnerships and Collaborations
11. Funding and Investment Analysis
12. Patent Analysis
13. Academic Grants Analysis
14. Key Commercialization Strategies
15. Promotional Analysis
16. Success Protocol Analysis
17. Novel Conjugation and Linker Technology Platforms
18. Assessment of Non-Clinical Data First in Human Dosing
19. Cost Price Analysis
20. Case Study 1: Contract Manufacturing of Antibody-Drug Conjugates
21. Case Study 2: Companion Diagnostics for Antibody-Drug Conjugate Therapeutics
22. SWOT Analysis
23. Market Sizing and Opportunity Analysis
24. Executive Insights
25. Conclusion
26. Appendix 1: Tabulated Data
27. Appendix 2: List of Companies and Organizations
To view more details on this report, click on the link:
https://www.rootsanalysis.com/....reports/view_documen
Learn from experts: do you know about these emerging industry trends?
Digital Therapies: The “Digital Pills” of current generation
Medical Device Coatings and Modification Technologies
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#antibodydrugconjugatemarketshare #antibodydrugconjugatemarkettrends #antibodydrugconjugates #adctherapeutics #antibodydrugconjugatecompanies
